Effect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTR Mutation

BACKGROUND: A new approach in the treatment of cystic fibrosis involves improving the function of mutant cystic fibrosis transmembrane conductance regulator (CFTR). VX-770, a CFTR potentiator, has been shown to increase the activity of wild-type and defective cell-surface CFTR in vitro. METHODS: We...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Accurso, Frank J., Rowe, Steven M., Clancy, J.P., Boyle, Michael P., Dunitz, Jordan M., Durie, Peter R., Sagel, Scott D., Hornick, Douglas B., Konstan, Michael W., Donaldson, Scott H., Moss, Richard B., Pilewski, Joseph M., Rubenstein, Ronald C., Uluer, Ahmet Z., Aitken, Moira L., Freedman, Steven D., Rose, Lynn M., Mayer-Hamblett, Nicole, Dong, Qunming, Zha, Jiuhong, Stone, Anne J., Olson, Eric R., Ordoñez, Claudia L., Campbell, Preston W., Ashlock, Melissa A., Ramsey, Bonnie W.
Formato: Artigo
Idioma:Inglês
Publicado em: 2010
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3148255/
https://ncbi.nlm.nih.gov/pubmed/21083385
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa0909825
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados